METTL3 and acute myeloid leukemia: This deficiency in METTL3 appears to facilitate AML-BM-MSC adipogenesis through RAC (Rho family)-alpha serine/threonine-protein kinase (AKT)-1 activation, with the potential of development resistance to chemotherapy of AML cells [141].